Immunome director sells 100,000 shares at $24.13
Isaac Barchas, a director at Immunome, executed a sale of 100,000 shares in a transaction disclosed in a recent SEC Form 4 filing.
The sale occurred as the company generated a 181% one-year total return as of the July 7, 2026 transaction date.
The company is currently developing its oncology pipeline with trailing-twelve-month revenue of $4.0 million and a net loss of $224.6 million.
Following this transaction, Isaac Barchas maintains a significant position, including 103,259 directly held shares and 108,504 shares held indirectly through AMBHMC II LLC.